Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
Saved in:
| Title: | Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. |
|---|---|
| Authors: | Piccart M; Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: martine.piccart@bordet.be., Hortobagyi GN; Department of Breast Medical Oncology, Multidisciplinary Breast Cancer Research Program, University of Texas MD Anderson Cancer Center, Houston, USA., Campone M; Institut de Cancérologie de l'Ouest, René Gauducheau, Centre de Recherche en Cancérologie, Nantes Saint Herblain, France., Pritchard KI; Department of Medicine, Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Canada., Lebrun F; Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Ito Y; Department of Breast Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo., Noguchi S; Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan., Perez A; Breast Cancer Centers, Memorial Cancer Institute, Hollywood., Rugo HS; Breast Oncology and Clinical Trials Education, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA., Deleu I; Oncologic Centre, AZ Nikolaas, Sint-Niklaas, Belgium., Burris HA 3rd; Sarah Cannon Research Institute, Nashville, USA., Provencher L; Centre des Maladies du Sein Deschênes-Fabia, CHU-Hôpital du Saint Sacrement, Québec, Canada., Neven P; Multidisciplinary Breast Centre and Department of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium., Gnant M; Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria., Shtivelband M; Ironwood Cancer & Research Centers, Chandler., Wu C; Novartis Pharmaceuticals Corporation, East Hanover., Fan J; Novartis Pharmaceuticals Corporation, East Hanover., Feng W; Novartis Pharmaceuticals Corporation, East Hanover., Taran T; Novartis Pharmaceuticals Corporation, East Hanover., Baselga J; Memorial Sloan-Kettering Cancer Center, New York, USA. |
| Source: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2014 Dec; Vol. 25 (12), pp. 2357-2362. Date of Electronic Publication: 2014 Sep 17. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
